Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05398029 | A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease | PHASE1 | COMPLETED | 13 | — | — | Jul 5, 2022 | Feb 14, 2025 | May 8, 2025 | 3 | New Zealand, United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose Escalation/Adaptive Design | EXPERIMENTAL | Participants will receive a single dose of VERVE-101 in multiple dose-escalation cohorts. |
| Part B: Single Dose Expansion | EXPERIMENTAL | Participants will receive a single dose of VERVE-101 selected based on the doses studied in Part A. |
| Name | Type | Description |
|---|---|---|
| VERVE-101 | DRUG | Intravenous (IV) infusion. |
Inclusion Criteria: * Male and/or female participants 18 up to 75 years at time of signing of informed consent * Female participants not of child-bearing potential * Diagnosis of HeFH * Established ASCVD Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with PCS...